Printer Friendly

STERLING WINTHROP, SCHERING AG, GERMANY, AND NYCOMED AS SIGN AGREEMENT FOR MAGNETIC RESONANCE IMAGING (MRI) PATENTS

 STERLING WINTHROP, SCHERING AG, GERMANY, AND NYCOMED AS
 SIGN AGREEMENT FOR MAGNETIC RESONANCE IMAGING (MRI) PATENTS
 NEW YORK, Aug. 11 /PRNewswire/ -- Sterling Winthrop Inc. announced today that Sterling Winthrop and Nycomed AS have entered into agreements with Schering AG, Germany, for certain rights to Schering AG, Germany's patents for magnetic resonance imaging (MRI).
 Under its licensing agreements with Nycomed AS and Schering AG, Sterling Winthrop will market, upon approval, Omniscan (gadodiamide), a contrast agent for MRI procedures developed by Sterling Winthrop under license from Nycomed AS. Sterling Winthrop's agreement with Schering AG also gives Schering AG certain options respect to certain MRI contrast agents in earlier stages of development by Sterling Winthrop. Sterling Winthrop's new drug application (NDA) for Omniscan is currently under review by the U.S. Food and Drug Administration, pending approval as a contrast agent for MRI of the central nervous system. The company anticipates NDA approval to market Omniscan this year.
 Sterling Winthrop Inc. is a worldwide manufacturer and marketer of pharmaceuticals and consumer health products. Omniscan products will be marketed in the United States by Sanofi Winthrop Pharmaceuticals, Sterling Winthrop's unit for the manufacture and marketing of pharmaceutical products and a leader in diagnostic imaging agents.
 -0- 8/11/92
 /CONTACT: Terry G. Kelley, 212-907-3009, or Carol J. Perlman, 212-907-2724, both of Sterling Winthrop/ CO: Sterling Winthrop, Schering AG, Nycomed AS ST: New York IN: MTC SU:


PS -- NY003 -- 8830 08/11/92 09:01 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Aug 11, 1992
Words:241
Previous Article:FREE EXTRA NIGHTS AT MARRIOTT'S FRENCHMAN'S REEF/MORNING STAR BEACH RESORTS, ST. THOMAS
Next Article:ONCOR INC. ANNOUNCES DEVELOPMENT OF NEW DNA PROBE THAT ALLOWS DIRECT DETECTION OF GENE AMPLIFIED IN BREAST CANCER CELLS
Topics:


Related Articles
METASYN AND NIPPON SHOJI KAISHA SIGN $3.5 MILLION AGREEMENT TO DEVELOP NOVEL MAGNETIC RESONANCE IMAGING DRUG
STERLING WINTHROP INC. AND ADVANCED MAGNETICS, INC. ANNOUNCE MRI CONTRAST AGENT LICENSE AND MARKETING AGREEMENT
IMCERA'S MALLINCKRODT MEDICAL UNIT ENTERS CROSS-LICENSE AGREEMENT WITH SCHERING, A.G. GERMANY FOR MRI PATENTS
NYCOMED AND VHA SIGN FIVE YEAR AGREEMENT
NYCOMED OPENS NEW CENTER FOR RESEARCH AND DEVELOPMENT; NEW FACILITY HOME TO WORLD'S MOST ADVANCED RESEARCH IN CONTRAST MEDIA
NYCOMED PRESIDENT DANIEL L. PETERS ELECTED TO THE PHARMACEUTICAL RESEARCH AND MANUFACTURERS ASSOCIATION BOARD OF DIRECTORS
HAFSLUND NYCOMED INVESTS IN DIATECH'S NOVEL RECEPTOR IMAGING TECHNOLOGY
Nycomed Inc. and Fujisawa USA, Inc., Enter into Marketing and Distribution Agreement for Iopamidol Injection, USP
Nycomed Inc. and UHC Announce New Three-Year Agreement
Nycomed Amersham Receives Market Clearance for Teslascan(R)

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters